Imatinib is approved by the FDA for the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). Imatinib potently inhibits a select set of tyrosine kinases at ...

Despite failing to achieve MRD-negativity after induction, patients with Ph+ acute lymphoblastic leukemia treated with ...

The preoperative management of patients with giant cell tumors in limb bones using denosumab therapy. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...

Pre-transplant measures of geriatric assessment domains and outcomes of allogeneic hematopoietic cell transplantation in adults aged 75 and older. This is an ASCO Meeting Abstract from the 2025 ASCO ...

Ibrahim Aldoss, MD, associate professor, City of Hope, explores recent findings on ponatinib as a first-line treatment for Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).

Ibrahim Aldoss, MD, discusses a post hoc analysis of ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who did not achieve early MRD negativity.

Find more information on the Altmetric Attention Score and how the score is calculated. Imatinib, a drug used for the treatment of chronic myeloid leukemia and other cancers, works by blocking the ...

However, we present a rare occurrence of severe hyperglycemia and newly elevated HbA1c in a patient on imatinib with no prior history of diabetes. It underscores the need for further research to ...

Here are 10 new shortages and discontinuations, according to drug supply databases from the FDA and the American Society of Health-System Pharmacists. Editor’s note: The drugs listed are in ...

Get article recommendations from ACS based on references in your Mendeley library. Pair your accounts.